Kobayashi Taiichiro, Fujiwara Sho, Ide Ayako, Toya Takashi, Shingai Naoki, Shimizu Hiroaki, Najima Yuho, Kobayashi Takeshi, Doki Noriko, Jo Aoi
Vaccine Clinic, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
Vaccines (Basel). 2025 Mar 5;13(3):275. doi: 10.3390/vaccines13030275.
: Hematopoietic stem cell transplantation (HSCT) can potentially cure hematological malignancies; however, post-transplant patients have a high risk of infection owing to their immunocompromised status. Vaccination against pathogens, such as diphtheria, tetanus, pertussis, and polio, is essential post-transplantation, but neither the long-term efficacy of vaccines nor the optimal vaccination schedule has been fully established. : In this prospective observational study, we assessed the short- and long-term immunogenicity of three doses of the diphtheria, tetanus, acellular pertussis, and inactivated poliovirus (DTaP-IPV) vaccines or DTaP vaccines in 29 adult allogeneic HSCT (allo-HSCT) recipients, with antibody levels measured at baseline, 1-3 months post-vaccination, and 1-year after vaccine completion. : At baseline, a substantial proportion of patients lacked protective antibody levels for the targeted pathogens. However, within 1-3 months post-vaccination, seropositivity rates significantly increased, reaching 78-100% for diphtheria, tetanus, pertussis, and poliovirus. Despite this, antibody levels significantly declined 1-year post-vaccination, especially for pertussis, with only 58-65% of patients maintaining protective levels. In contrast, 85-96% of patients retained protective levels for diphtheria, tetanus, and poliovirus, although antibody values also decreased. Compared to human leukocyte antigen (HLA)-mismatched cases, HLA-matched cases showed significantly higher antibody levels for diphtheria, pertussis, and poliovirus types 1 and 3. : This study demonstrates the short-term effectiveness of DTaP-IPV and DTaP vaccines in adult allo-HSCT patients but emphasizes the challenge of maintaining long-term immunity. Given the difficulties in sustaining long-term vaccine efficacy in allo-HSCT recipients, particularly in HLA-mismatched cases, re-evaluating the current vaccination schedule may be necessary to maintain protection.
造血干细胞移植(HSCT)有可能治愈血液系统恶性肿瘤;然而,移植后的患者由于免疫功能低下,感染风险很高。接种针对白喉、破伤风、百日咳和脊髓灰质炎等病原体的疫苗在移植后至关重要,但疫苗的长期疗效和最佳接种时间表均尚未完全确定。
在这项前瞻性观察研究中,我们评估了29名成年异基因造血干细胞移植(allo-HSCT)受者接种三剂白喉、破伤风、无细胞百日咳和灭活脊髓灰质炎病毒(DTaP-IPV)疫苗或DTaP疫苗后的短期和长期免疫原性,在基线、接种后1至3个月以及完成疫苗接种1年后测量抗体水平。
在基线时,相当一部分患者缺乏针对目标病原体的保护性抗体水平。然而,在接种后1至3个月内,血清阳性率显著增加,白喉、破伤风、百日咳和脊髓灰质炎病毒的血清阳性率达到78%至100%。尽管如此,接种疫苗1年后抗体水平显著下降,尤其是百日咳,只有58%至65%的患者维持保护性水平。相比之下,85%至96%的患者对白喉、破伤风和脊髓灰质炎病毒保持保护性水平,尽管抗体值也有所下降。与人类白细胞抗原(HLA)不匹配的病例相比,HLA匹配的病例对白喉、百日咳以及1型和3型脊髓灰质炎病毒显示出显著更高的抗体水平。
这项研究证明了DTaP-IPV和DTaP疫苗在成年allo-HSCT患者中的短期有效性,但强调了维持长期免疫力的挑战。鉴于在allo-HSCT受者中维持疫苗长期疗效存在困难,特别是在HLA不匹配的病例中,可能有必要重新评估当前的接种时间表以维持保护作用。